Related Experiment Video
Updated: May 10, 2026
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
NLRP3 inflammasome: a key player in neonatal brain injury
Cagla Kiser1,2, Ilkcan Ercan1, Defne Engur3
1Izmir Biomedicine and Genome Center, Dokuz Eylul University Health Campus, Izmir, Turkey.
Abstract:
Among neonates, hypoxic-ischemic encephalopathy is the most significant cause of mortality and hypoxia-ischemia is among the leading causes of brain damage. The microglia are primary mediators of neuroinflammation. NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation is the first line of defense in the central nervous system. Numerous studies have shown that the NLRP3 inflammasome is activated and proinflammatory cytokines are upregulated upon hypoxia-ischemia-induced brain damage. However, aberrant activation of the NLRP3 inflammasome results in cell death and brain tissue damage. Given that neonates are particularly vulnerable to neuroinflammation, which may cause lifelong disabilities, it is important to target the pathways involved in its complex nature to improve their prognosis. The potential use of compounds or drugs that target inflammasome activation to relieve hypoxia-induced brain damage has become significant. This review describes the NLRP3 inflammasome in neonates to contribute to the development of therapeutic approaches.
Insights
Neonatal hypoxic-ischemic encephalopathy causes brain damage. Targeting the NLRP3 inflammasome pathway may reduce neuroinflammation and improve outcomes for affected newborns.
Area of Science:
- Neuroscience
- Immunology
- Neonatology
Background:
- Hypoxic-ischemic encephalopathy (HIE) is a major cause of neonatal mortality and brain damage.
- Microglia are key players in neuroinflammation, and NLRP3 inflammasome activation is a critical component of the central nervous system's response.
- While NLRP3 inflammasome activation is a defense mechanism, its aberrant activation contributes to cell death and tissue damage in HIE.
Purpose of the Study:
- To review the role of the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome in neonatal hypoxic-ischemic brain injury.
- To highlight the significance of targeting inflammasome pathways for therapeutic development in neonates.
- To provide insights into the complex neuroinflammatory processes in vulnerable newborns.
Main Methods:
- Literature review focusing on NLRP3 inflammasome activation in neonatal hypoxia-ischemia.
- Analysis of studies investigating pro-inflammatory cytokine upregulation and cell death mechanisms.
- Synthesis of current understanding regarding therapeutic strategies targeting inflammasomes.
Main Results:
- NLRP3 inflammasome activation and pro-inflammatory cytokine release are consistently observed in hypoxia-ischemia-induced brain damage in neonates.
- Aberrant NLRP3 inflammasome activation leads to detrimental cell death and exacerbates brain tissue damage.
- Neonates exhibit particular vulnerability to neuroinflammation, potentially leading to long-term disabilities.
Conclusions:
- The NLRP3 inflammasome plays a critical role in neonatal hypoxic-ischemic brain injury.
- Therapeutic strategies targeting NLRP3 inflammasome activation hold promise for mitigating brain damage and improving prognosis in neonates.
- Further research into inflammasome modulation is crucial for developing effective treatments for HIE.
More Related Videos
06:52Detection of Inflammasome Activation and Pyroptotic Cell Death in Murine Bone Marrow-derived Macrophages
Published on: May 21, 2018
08:50A Murine Model of Fetal Exposure to Maternal Inflammation to Study the Effects of Acute Chorioamnionitis on Newborn Intestinal Development
Published on: June 24, 2020
